Anita D'souza
Expertise in
15
conditions

Dr. Anita D'souza

Hematology | Oncology
8800 W. Doyne Ave., 
Milwaukee, WI 
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
15
conditions
8800 W. Doyne Ave., 
Milwaukee, WI 

Overview

Dr. Anita D’Souza is a professor of medicine (hematology/oncology). She completed her medical school from Goa Medical College, India where she graduated at the top of her class and was awarded Best Medical Graduate. She completed her internal medicine residency from William Beaumont Hospital in Michigan where she received the Zimmerman Award for Outstanding Clinical Judgment, Leadership, and Integrity. She completed her hematology/oncology fellowship from the Mayo Clinic in Rochester, Minnesota. She is a past recipient of the Daniel McCarty Award for Research Excellent and Women in Science Rising Pioneer Award at MCW.

Dr. D'souza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy.

Dr. D'souza is board certified in Internal Medicine and Medical Oncology And Hematology. She is actively involved in clinical research, co-authoring 248 peer reviewed articles and participating in 5 clinical trials. Dr. D'souza is currently accepting new patients.

Residency

William Beaumont Hospital - Royal Oak - MI - Residency in Internal Medicine - (2010)

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Board Certifications

Internal Medicine
Medical Oncology And Hematology

Fellowships

Mayo Clinic - Rochester - MN - Fellowship in Hematology and Oncology - (2013)

Hospital Affiliations

Froedtert Memorial Lutheran Hospital

Languages Spoken

English
Hindi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Clinical Cancer Center - Froedtert Hospital
8800 W. Doyne Ave., Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
Enrollment Status: Completed
Publish Date: April 09, 2026
Intervention Type: Drug
Study Drugs: TAK-079, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

248 Total Publications

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Journal: Science translational medicine
Published: May 27, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Expertise in
3
conditions
Dr. Robert Montgomery
Hematology | Oncology
Referral may be required

Childrens Hospital Of Wisconsin Inc

8915 W Connell Ave, 
Milwaukee, WI 
 (0.1 miles away)
414-257-2424
Languages Spoken:
English
See accepted insurances

Robert Montgomery is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Montgomery is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Blood Clots, Hemophilia A, Hemophilia B, and Bone Marrow Transplant.

Expertise in
11
conditions
Dr. Binod Dhakal
Hematology | Oncology
Expertise in
11
conditions
Dr. Binod Dhakal
Hematology | Oncology
Referral may be required

Clinical Cancer Center - Froedtert Hospital

8800 W. Doyne Ave., 
Milwaukee, WI 
 (0.3 miles away)
414-805-0505
Languages Spoken:
English, Hindi, Nepali
See accepted insurances
Accepting New Patients
Offers Telehealth

Binod Dhakal, MD, MS, is an associate professor of medicine (hematology and oncology) at the Medical College of Wisconsin, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed internal medicine residency at Saint Francis Hospital, Evanston, IL, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a chief fellow. Prior to joining the fellowship, he was an assistant professor of medicine (general internal medicine) at the Medical College in Wisconsin. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; Medical College of Wisconsin Affiliated Hospitals (MCWAH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science. His current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials. Dr. Dhakal is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dhakal is currently accepting new patients.

Expertise in
12
conditions
Dr. Mary Eapen
Hematology | Oncology
Expertise in
12
conditions
Dr. Mary Eapen
Hematology | Oncology
Referral may be required

Clinical Cancer Center-Froedtert Hospital

8800 W Doyne Ave, 
Milwaukee, WI 
 (0.3 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances

Mary Eapen is a Hematologist and an Oncologist practicing medicine in Milwaukee, Wisconsin. Dr. Eapen is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Anemia, Aplastic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Anita D'souza

How do I make an appointment with Dr. Anita D'souza?

You can book an appointment with Dr. Anita D'souza by calling their office at 414-805-0505. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anita D'souza a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anita D'souza is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anita D'souza specialize in?

While Dr. Anita D'souza is a Hematology, they have specific expertise in Multiple Myeloma, Primary Amyloidosis, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anita D'souza participate in research or clinical trials?

Yes. Dr. Anita D'souza has published 248 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Anita D'souza's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anita D'souza accept my insurance?

Dr. Anita D'souza accepts most major insurance plans, including Anthem BCBS and Aspirus Arise Health. We recommend calling the office directly at 414-805-0505 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. D'souza's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile